Evidence map›Paper›PMID 29311992›Full record

ArticleFrontiers in physiology2017

Empagliflozin Limits Myocardial Infarction

Ioanna Andreadou, Panagiotis Efentakis, Evangelos Balafas, Gabriele Togliatto, Constantinos H Davos, Aimilia Varela, Constantinos A Dimitriou, Panagiota-Efstathia Nikolaou, Eirini Maratou, Vaia Lambadiari and 5 more

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 93 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 2 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04780438 early_phase1unknown statusnot on this mapstarted 2021, after this paper: background citation

Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.

TypeinterventionalSponsorG.Gennimatas General HospitalRan2021 to 2023Enrolled350ConditionsAtrial Fibrillation Recurrent, Pulmonary Venous Isolation, Catheter Ablation, Sodium-glucose Co-transporter 2 InhibitorsArmsDapagliflozin, Placebo
NCT06187727 phase4completednot on this mapstarted 2023, after this paper: background citation

Clinical Study on Reducing Myocardial Infarction Siez After Primary PCI in Patients With ST Segment Elevation Myocardial Infarction by Using Henagliflozin

TypeinterventionalSponsorQian gengRan2023 to 2025Enrolled248ConditionsMyocardial Infarction, Heart FailureArmsHenagliflozin
3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 2 syntheses or guidelines pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. The use of SGLT2 inhibitors in older people: What is important?Aging clinical and experimental research · 2025
    Review
  19. Article
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Ioanna AndreadouLaboratory of Pharmacology, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
Panagiotis EfentakisLaboratory of Pharmacology, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
Evangelos BalafasAcademy of Athens Biomedical Research Foundation, Centre of Clinical Experimental Surgery and Translational Research, Athens, Greece.
Gabriele TogliattoDepartment of Medical Sciences, University of Turin, Turin, Italy.
Constantinos H DavosCardiovascular Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece.
Aimilia VarelaCardiovascular Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece.
Constantinos A DimitriouCardiovascular Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece.
Panagiota-Efstathia NikolaouLaboratory of Pharmacology, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
Eirini MaratouHellenic National Center for Research, Prevention and Treatment of Diabetes Mellitus and Its Complications, Athens, Greece.
Vaia Lambadiari2nd Department of Internal Medicine, Research Institute and Diabetes Center, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens, Greece.
Ignatios Ikonomidis2nd University Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Nikolaos KostomitsopoulosAcademy of Athens Biomedical Research Foundation, Centre of Clinical Experimental Surgery and Translational Research, Athens, Greece.
Maria F BrizziDepartment of Medical Sciences, University of Turin, Turin, Italy.
George Dimitriadis2nd Department of Internal Medicine, Research Institute and Diabetes Center, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens, Greece.
Efstathios K Iliodromitis2nd University Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GRAcademy of Athens · GRUniversity of Turin · ITHellenic Center for Disease Control & Prevention · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Empagliflozin (EMPA), a drug approved for type 2 diabetes management, reduced cardiovascular death but is unknown if it reduces myocardial infarction. We sought to investigate: (i) the effect of EMPA on myocardial function and infarct size after ischemia/reperfusion in mice fed with western diet (WD), (ii) the underlying signaling pathways, (iii) its effects on cell survival in rat embryonic-heart-derived cardiomyoblasts (H9C2) and endothelial cells (ECs). To facilitate the aforementioned aims, mice were initially randomized in Control and EMPA groups and were subjected to 30 min ischemia and 2 h reperfusion. EMPA reduced body weight, blood glucose levels, and mean arterial pressure. Cholesterol, triglyceride, and AGEs remained unchanged. Left ventricular fractional shortening was improved (43.97 ± 0.92 vs. 40.75 ± 0.61%) and infarct size reduced (33.2 ± 0.01 vs. 17.6 ± 0.02%). In a second series of experiments, mice were subjected to the above interventions up to the 10th min of reperfusion and myocardial biopsies were obtained for assessment of the signaling cascade. STAT3 was increased in parallel with reduced levels of malondialdehyde (MDA) and reduced expression of myocardial iNOS and interleukin-6. Cell viability and ATP content were increased in H9C2 and in ECs. While, STAT3 phosphorylation is known to bestow infarct sparing properties through interaction with mitochondria, we observed that EMPA did not directly alter the mitochondrial calcium retention capacity (CRC); therefore, its effect in reducing myocardial infarction is STAT3 dependent. In conclusion, EMPA improves myocardial function and reduces infarct size as well as improves redox regulation by decreasing iNOS expression and subsequently lipid peroxidation as shown by its surrogate marker MDA. The mechanisms of action implicate the activation of STAT3 anti-oxidant and anti-inflammatory properties.

Indexed as

cardiac functioncardioprotectionempagliflozininfarct sizemolecular signalingSTAT3 pathway

Identifiers

PMID29311992
PMCPMC5742117
OpenAlexW2775930384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.